GlassScriptPhysician profile
Julia A Brookman
NPI 1710207972
$6,284.62
in general payments reported to CMS, 2019-2025
25 companies · $679 in 2025
The $679 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $44.37 · 2021: $3,141 · 2022: $257 · 2023: $415 · 2024: $199 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,595.11 | 2019-2022 | |
| Smith+Nephew, INC. | $301.71 | 2019-2023 | Collagenase Santyl |
| Davol INC. | $292.93 | 2022-2024 | Phasix Mesh |
| Abbott Laboratories | $164.12 | 2023 | Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $150.76 | 2024-2025 | |
| Janssen Biotech, INC. | $113.12 | 2024-2025 | Talvey, Tecvayli, Carvykti |
| Daiichi Sankyo INC. | $90.55 | 2025 | Enhertu, Datroway, Injectafer |
| Tela Bio, INC. | $58.13 | 2024 | Ovitex 2s |
| Sobi, INC | $55.87 | 2024-2025 | |
| Lilly USA, LLC | $53.70 | 2025 | Verzenio, Jaypirca |
| Tactile Systems Technology INC | $44.37 | 2020 | |
| Pfizer INC. | $39.91 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.84 | 2025 | Fruzaqla, Iclusig |
| Novartis Pharmaceuticals Corporation | $35.76 | 2025 | |
| Tersera Therapeutics LLC | $35.05 | 2025 | Zoladex |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32.88 | 2024-2025 | |
| Incyte Corporation | $32.54 | 2025 | Jakafi, Zynyz, Monjuvi |
| Astellas Pharma US INC | $27.08 | 2024 | Vyloy |
| Genmab U.S., INC. | $22.95 | 2025 | Tivdak |
| Caris Mpi, INC. | $19.24 | 2025 | Mi Cancer Seek |
| Novocure INC. | $17.36 | 2025 | Optune Lua (Novottf-200t) |
| Phadia US INC. | $16.72 | 2023 | Immunocap |
| Kci USA, INC. | $16.49 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.23 | 2025 | |
| Genentech USA, INC. | $14.20 | 2025 | Polivy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Brookman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.